Cover Story
Lomustine, a.k.a. CCNU, is an old cancer drug.
By Matthew Bin Han Ong
By Matthew Bin Han Ong
In Brief
Clinical Roundup
NCI Trials
NCI Trials for November 2019
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
Trending Stories
- Karen Knudsen to leave ACS
- A $150M gift enables City of Hope to establish $1M Stephenson Prize in pancreatic cancer research, build research program focused on the disease
- Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis shows
Subgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies - Jeffrey S. Weber, pioneering immunologist and melanoma expert at NYU, dies at 72
- Tumors are able to form with no DNA mutations, fly study shows
- From clinician scientist to nonprofit CEO